Back

Pharmacological interventions for COVID-19: Protocol for a Rapid Living Systematic Review with network meta-analysis

Pinto, A. C. P. N.; Rocha, A. P.; Milby, K. M. M.; Rocha Filho, C. R.; Reis, F. S. A.; Carvas Junior, N.; Civile, V. T.; Santos, R. R. P.; Trevisani, G. F. M.; Ferla, L. J.; Ramalho, G. S.; Puga, M. E. S.; Trevisani, V. F. M.; Atallah, A. N.

2020-05-06 infectious diseases
10.1101/2020.05.02.20088823 medRxiv
Show abstract

CONTEXT AND OBJECTIVECoronavirus disease 2019 (COVID-19) has emerged in China in December 2019 and rapidly spread. Although extraordinary efforts have been made on research regarding pharmacological interventions, none have proven effective. This is the protocol for a rapid living systematic review that aims to compare the effectiveness and safety of different pharmacological interventions for the treatment of COVID-19. METHODSrapid living systematic review methodology with Network Meta-Analysis following the recommendations of Cochrane Handbook. We will include randomized controlled trials (RCT) and quasi-RCTs that evaluate single and/or combined pharmacological interventions at any dose for the treatment of COVID-19. We will search PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), LILACS, Scopus and SciELO to identify potentially eligible studies. No language restrictions will be used in the selection. We will perform the critical appraisal of included studies with the Risk of Bias tool and the certainty of evidence will be evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE).

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.